MEK抑制剂司美替尼联合同步胸部放疗治疗非小细胞肺癌的I期试验
这项单臂、单中心、开放标签I期试验在21例III期不适合同步放化疗或IV期有 dominant 胸部症状的非小细胞肺癌患者中,评估口服司美替尼(起始50 mg每日两次,放疗前7天开始)联合同步胸部放疗(60-66 Gy/30-33次)的推荐II期剂量(RP2D)。结果显示未增强放疗相关毒性,但常见3-4级淋巴细胞减少(19/21)和高血压(7/21),6例发生确诊/疑似肺孢子菌肺炎,中位随访时仅2例存活,主要失败模式为远处转移,作者认为不应开展II期试验。
要点
- 司美替尼联合同步胸部放疗未增强放疗相关毒性,但3-4级淋巴细胞减少发生率极高(19/21)。
- 6例患者发生确诊或临床疑似肺孢子菌肺炎,提示免疫抑制风险。
- 主要首次进展模式为远处转移±局部区域进展(12/21,57.1%)。
核心结论
- 在RP2D下联合同步胸部放疗与司美替尼治疗的非小细胞肺癌患者中, outcome 差且多数出现严重淋巴细胞减少,并导致确诊/临床疑似肺孢子菌肺炎;该联合方案不应继续开展II期试验。
研究设计与样本
- 单臂、单中心、开放标签I期试验,采用Fibonacci 3+3剂量爬坡(最大18例)后扩展队列15例,计划入组33例,实际入组21例。
- 入组患者为III期不适合同步放化疗或IV期有 dominant 胸部症状的非小细胞肺癌患者。
- 司美替尼口服每日两次(起始剂量50 mg),放疗前7天开始,同步胸部放疗6-6.5周,60-66 Gy/30-33次。
- 主要目标为确定司美替尼联合同步胸部放疗的推荐II期剂量(RP2D)。
主要发现
- 21例患者入组(2010年6月至2015年2月),中位年龄62岁(范围50-73),男12例(57%)、女9例(43%)。
- ECOG PS 0分7例(33%)、1分14例(67%);III期16例(76%)、IV期5例(24%);中位GTV 64 cm3(范围1-224 cm3)。
- 所有21例均按计划完成胸部放疗并接受诱导化疗;13例(62%)接受司美替尼全剂量。
- 起始队列未见放疗相关毒性增强;2例发生剂量限制性毒性(1例3级腹泻/乏力,1例肺栓塞)。
- 最常见3-4级不良事件为淋巴细胞减少(19/21)和高血压(7/21);1例发生3级食管炎;无≥3级放射性肺炎。
关键数值与推荐
- 推荐II期剂量(RP2D)为司美替尼50 mg口服每日两次,放疗前7天开始联合同步胸部放疗60-66 Gy/30-33次。
- 剂量限制性毒性定义下观察到2例事件:3级腹泻/乏力和肺栓塞各1例。
- 3-4级淋巴细胞减少19/21例,3-4级高血压7/21例。
- 确诊/疑似肺孢子菌肺炎6例。
临床怎么用
- 该联合方案在RP2D下未增强放疗相关毒性,但严重淋巴细胞减少和肺孢子菌肺炎风险突出,不应在II期试验中继续探索。
- 临床使用MEK抑制剂联合同步胸部放疗时需密切监测淋巴细胞计数及感染征象,尤其警惕肺孢子菌肺炎。
- 该人群主要失败模式为远处转移,提示需关注全身疾病控制。
局限性
- 单臂、单中心、开放标签设计,样本量小(21例),未设对照组。
- 研究终止于I期,未评估疗效终点。
- 部分患者随访时间有限,分析时仅2例存活。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The RAS/RAF/MEK/ERK signalling pathway has a pivotal role in cancer proliferation and modulating treatment response. Selumetinib inhibits MEK and enhances effects of radiotherapy in preclinical studies. PATIENTS AND METHODS: Single-arm, single-centre, open-label phase I trial. Patients with stage III NSCLC unsuitable for concurrent chemo-radiotherapy, or stage IV with dominant thoracic symptoms, were recruited to a dose-finding stage (Fibonacci 3 + 3 design; maximum number = 18) then an expanded cohort (n = 15). Oral selumetinib was administered twice daily (starting dose 50 mg) commencing 7 days prior to thoracic radiotherapy, then with radiotherapy (6-6.5 weeks; 60-66 Gy/30-33 fractions). The primary objective was to determine the recommended phase II dose (RP2D) of selumetinib in combination with thoracic radiotherapy. RESULTS: 21 patients were enrolled (06/2010-02/2015). Median age: 62y (range 50-73). M:F ratio 12(57%):9(43%). ECOG PS 0:1, 7(33%):14(67%). Stage III 16(76%); IV 5(24%). Median GTV 64 cm3 (range 1-224 cm3). 15 patients comprised the expanded cohort at starting dose. All 21 patients completed thoracic radiotherapy as planned and received induction chemotherapy. 13 (62%) patients received the full dose of selumetinib.In the starting cohort no enhanced radiotherapy-related toxicity was seen. Two patients had dose-limiting toxicity (1x grade 3 diarrhoea/fatigue and 1x pulmonary embolism). Commonest grade 3-4 adverse events: lymphopaenia (19/21 patients) and hypertension (7/21 patients). One patient developed grade 3 oesophagitis. No patients developed grade ≥3 radiation pneumonitis. Two patients were alive at the time of analysis (24 and 26 months follow-up, respectively). Main cause of first disease progression: distant metastases ± locoregional progression (12/21 [57.1%] patients). Six patients had confirmed/suspected pneumocystis jiroveci pneumonia. CONCLUSION: We report poor outcome and severe lymphopenia in most patients treated with thoracic radiotherapy and selumetinib at RP2D in combination, contributing to confirmed/clinically suspected pneumocystis jiroveci pneumonia. These results suggest that this combination should not be pursued in a phase II trial.ClinicalTrials.gov reference: NCT01146756.
引用
- Haslett K, Koh P, Hudson A, et al. Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer. Clin Transl Radiat Oncol. 2021. PMID: 33748440. doi:10.1016/j.ctro.2021.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。